These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25491470)

  • 41. [Treatment and prognosis of juvenile parkinsonism--L-dopa responsiveness].
    Takubo H
    Nihon Rinsho; 1997 Jan; 55(1):101-5. PubMed ID: 9014430
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Levodopa unresponsive symptoms in Parkinson disease.
    Sethi K
    Mov Disord; 2008; 23 Suppl 3():S521-33. PubMed ID: 18781679
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impulse control disorders in Parkinson's disease in a Chinese population.
    Fan W; Ding H; Ma J; Chan P
    Neurosci Lett; 2009 Nov; 465(1):6-9. PubMed ID: 19560522
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatments for Parkinson disease--past achievements and current clinical needs.
    Poewe W
    Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impulsive and compulsive behaviors in Parkinson's disease.
    Evans AH; Strafella AP; Weintraub D; Stacy M
    Mov Disord; 2009 Aug; 24(11):1561-70. PubMed ID: 19526584
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Levodopa: effect on cell death and the natural history of Parkinson's disease.
    Olanow CW
    Mov Disord; 2015 Jan; 30(1):37-44. PubMed ID: 25502620
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Experience with levodopa/carbidopa intestinal gel in the treatment of advanced Parkinson's disease in Hungary].
    Nagy H; Takáts A; Tóth A; Bereczki D; Klivényi P; Dézsi L; Dibó G; Vécsei L; Kovács N; Aschermann Z; Komoly S; Varannai L; Zemlényi G; Valikovics A
    Ideggyogy Sz; 2014 Nov; 67(11-12):385-9. PubMed ID: 25720240
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon.
    Tse W
    J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):12-7. PubMed ID: 17948614
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.
    Gottwald MD
    Pharmacotherapy; 1999 Nov; 19(11 Pt 2):162S-8S. PubMed ID: 10555944
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Motor complications of treatment with levodopa in Parkinson's disease].
    García-Escrig M; Bermejo-Pareja F
    Rev Neurol; 1999 Apr 16-30; 28(8):799-809. PubMed ID: 10363326
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Olanow CW; Obeso JA; Stocchi F
    Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
    Pahwa R
    J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapies in Parkinson's disease.
    Jankovic J; Poewe W
    Curr Opin Neurol; 2012 Aug; 25(4):433-47. PubMed ID: 22691758
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa].
    Svetel MV; Sternić NM; Filipović SR; Vojvodić NM; Kostić VS
    Srp Arh Celok Lek; 1997; 125(7-8):203-6. PubMed ID: 9304232
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.
    Stacy M; Galbreath A
    Clin Neuropharmacol; 2008; 31(1):51-6. PubMed ID: 18303491
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Surgical approach to l-dopa-induced dyskinesias.
    Sankar T; Lozano AM
    Int Rev Neurobiol; 2011; 98():151-71. PubMed ID: 21907086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.